Clinical trials: Acute Leukaemia
Acute Leukemia
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 ([14C])-revumenib in participants with acute leukemia.
- Trial name
- NCT05406817
- Testing
- Revumenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Syndax Pharmaceuticals
Leukemia, Myelomonocytic, Acute
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy…
- Trial name
- NCT00363974
- Testing
- XIAP antisense
- Where
- 7 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Aegera Therapeutics
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The main purpose of this study are to determine the recommended Phase 2 dose(s) (RP2D) route of administration, schedule and the maximum tolerated dose (MTD) in Part 1 and to determine the safety and tolerability of JNJ-67571244…
- Trial name
- NCT03915379
- Testing
- JNJ-67571244
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Nonlymphocytic, Acute
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
The purpose of this study is to evaluate the effectiveness (response rate) and safety of tipifarnib in patients with refractory or relapsed AML.
- Trial name
- NCT00354146
- Testing
- tipifarnib (R115777)
- Volunteers
- 252 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Solid Tumors
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02587598
- Testing
- INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine
- Where
- 19 sites in United States
- Volunteers
- 97 people
- Sponsor
- Incyte Corporation
B Acute Lymphoblastic Leukemia/Lymphoma
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
- Trial name
- NCT07196111
- Testing
- BAFFR CAR-T
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Acute Lymphoblastic Leukemia
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Outcomes for children with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) are dismal. Therefore, the investigators performed this multicenter, phase II study to evaluate the efficacy and , safety and pharmacokinetic…
- Trial name
- NCT02544789
- Testing
- Clofarabine
- Where
- 6 sites in China
- Volunteers
- 44 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Acute Lymphoblastic Leukemia
A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia
The purpose of this study is primarily to assess the safety, tolerability and pharmacokinetics (PK) of clofarabine intravenously administered to pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or…
- Trial name
- NCT01196013
- Testing
- Clofarabine
- Where
- 9 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Genzyme, a Sanofi Company
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with…
- Trial name
- NCT00374296
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Mirati Therapeutics Inc.
Acute Myeloid Leukemia
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
- Trial name
- NCT01034410
- Testing
- AS1411, Cytarabine
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- Antisoma Research
Relapsed Adult AML
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.
- Trial name
- NCT06613217
- Testing
- zelenirstat
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Pacylex Pharmaceuticals
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
This study will evaluate the long-term safety of ARD103 cellular therapies
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT06906380
- Testing
- Non interventional study
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- ARCE Therapeutics, Inc.
Leukemia, Myeloid, Acute
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
The purpose of this study is to evaluate the efficacy and safety of Oral Azacitidine (CC-486) in Chinese participants with acute myeloid leukemia in complete remission.
- Trial name
- NCT05413018
- Testing
- CC-486
- Where
- 34 sites in China
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
AML (Acute Myeloid Leukemia)
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults.
- Trial name
- NCT07751991
- Testing
- CHM-029
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Charm Therapeutics
Relapsed/Refractory Acute Myeloid Leukemia
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who…
- Trial name
- NCT06549790
- Testing
- NMS-03597812
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- Nerviano Medical Sciences
Secondary AML, Myelofibrosis
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned…
- Trial name
- NCT07250646
- Testing
- rebecsinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aspera Biomedicines, Inc.
Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
This is an open-label, multi-cohort, multi-center Phase Ib/II clinical study to evaluate the tolerance and efficacy of Mitoxantrone Hydrochloride liposome injection combined with cytarabine in patients with Acute Myeloid Leukemia…
- Trial name
- NCT05100303
- Testing
- Mitoxantrone Hydrochloride liposome injection, Cytarabine (LoDAC)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Leukemia, Myeloid
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
- Trial name
- NCT00512083
- Testing
- AS1411
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 70 people
- Sponsor
- Antisoma Research
Acute Myeloid Leukemia, Relapsed Adult AML
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML.
- Trial name
- NCT03932318
- Testing
- Lintuzumab-Ac225, Venetoclax, Azacitidine
- Sponsor
- Actinium Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.